Rutgers Cancer Institute of New Jersey: Identification of Tamoxifen Resistance Markers Can Play Role in Breast Cancer Treatment Planning
January 26, 2021
January 26, 2021
NEW BRUNSWICK, New Jersey, Jan. 26 (TNSJou) -- Rutgers Cancer Institute of New Jersey issued the following news:
One common challenge of cancer therapy is when cancer cells don't respond to a drug that is usually able to kill or weaken them, known as treatment resistance. Tamoxifen is a drug that blocks the activity of estrogen in the breast, commonly used to treat patients with estrogen-receptor (ER) positive breast cancer. In a recent study, researchers from Rutgers University exp . . .
One common challenge of cancer therapy is when cancer cells don't respond to a drug that is usually able to kill or weaken them, known as treatment resistance. Tamoxifen is a drug that blocks the activity of estrogen in the breast, commonly used to treat patients with estrogen-receptor (ER) positive breast cancer. In a recent study, researchers from Rutgers University exp . . .